[18F]FPDTG

`[18F]FPDTG` (also referred to as `[18F]FPTDG` or `3-[18F]fluorophenylthio-digalactoside`) is a fluorine-18 labeled glycomimetic radiotracer developed by Wayne State University and the Karmanos Cancer Institute. It is designed for positron emission tomography (PET) imaging of galectin-3 (Gal-3) expression, which is significantly overexpressed in breast carcinomas compared to pre-malignant or benign lesions. By targeting Gal-3 with high binding affinity (Kd of 14 nM) and specificity, `[18F]FPDTG` serves as a diagnostic imaging agent for the early detection and differential diagnosis of malignant versus benign breast lesions, particularly in patients with dense breast tissue where mammography has limited sensitivity.

Other names

18F-FPDTG18F-FPTDG3-[18F]fluorophenylthio-digalactoside[18F]FPDTG[18F]FPTDG